Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 6Rhabdomyosarcoma 5Sarcoma, Synovial 3Osteosarcoma 3Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Wilms Tumor 1Retinoblastoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Malignant mesenchymal tumor 1Histiocytoma, Malignant Fibrous 1Hepatoblastoma 1Hemangiopericytoma, Malignant 1Desmoplastic Small Round Cell Tumor 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1Adrenocortical Carcinoma 1

Interventions

Cyclophosphamide 9Doxorubicin 8Vincristine 6Etoposide 6Ifosfamide 5Filgrastim 5Radiotherapy 4fludarabine phosphate 3Topotecan 3Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Cisplatin 3Carboplatin 3seclidemstat 2Temozolomide 2Tacrolimus 2Neoadjuvant Therapy 2Irinotecan 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Granulocyte Colony-Stimulating Factor 2Epirubicin 2Dactinomycin 2Cytoreduction Surgical Procedures 2Cyclosporine 2Chemotherapy, Adjuvant 2Brachytherapy 2thymoglobulin 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Desmoplastic Small Round Cell Tumor × cixutumumab × Sarcoma × Clear all
NCT00720174 2016-05-17

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Sarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡